Adding the CDK4/6 inhibitor abemaciclib to Faslodex (fulvestrant) is a promising way to treat patients with an advanced breast cancer who experienced a relapse or had their disease progress after endocrine therapy, clinical trial results indicate.
The MONARCH Phase 3 trial covered patients with hormone receptor (HR)-positive, HER2-negative breast cancer. The combination therapy significantly improved patients’ time to disease progression or death, compared with patients who received Faslodex plus a placebo, according to abemaciclib’s maker, Lilly Oncology.
“We are excited about the outcome of our first Phase 3 study for abemaciclib. These data are an important milestone in our goal of bringing abemaciclib to patients with advanced breast cancer, and we look forward to our upcoming conversations with regulators,” Levi Garraway, MD, PhD, senior vice president of global development and medical affairs at Lilly Oncology, said in a news release. “This is another example of Lilly’s commitment to delivering breakthrough treatments and improving outcomes for patients with cancer.”
Lilly is conducting several MONARCH trials in addition to the MONARCH Phase 3 study that has been completed.
The global MONARCH 2 study (NCT02107703) is a randomized, double-blind, placebo-controlled trial….
Our team is comprised of Bob and Linda Carey, our advisors and volunteers. Without them, changing lives one smile at a time would never be possible!
